Targeting survivin in cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 4, 2008, Pages 463-476

  Pennati, Marzia ^a   Folini, Marco ^a   Zaffaroni, Nadia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Antisense oligonucleotides; Apoptosis; Cell cyde; Dominant negative mutants; Human cancers; Inhibitor of apoptosis proteins; Ribozymes; Small interfering RNAs; Survivin

Indexed keywords

4 (6 CYCLOHEXYLMETHOXY 9H PURIN 2 YLAMINO) N,N DIETHYLBENZAMIDE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BETA CATENIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; DENDRITIC CELL VACCINE; EM 1421; FLAVOPIRIDOL; FLUOROURACIL; HEAT SHOCK PROTEIN 90 INHIBITOR; HLA A2 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; LY 2181308; NU 6140; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN KINASE B; PURVALANOL A; RIBOZYME; SHEPHERDIN; SMALL INTERFERING RNA; STAT3 PROTEIN; SURVIVIN; TETRA O METHYLNORHYDROGUAIARETIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN; YM 155; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; TUMOR PROTEIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER STAGING; CLINICAL TRIAL; COLON CANCER; DRUG EFFICACY; DRUG TARGETING; GENE MUTATION; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; IMMUNOTHERAPY; MELANOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; UTERINE CERVIX CANCER; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASMS;

EID: 42149092791     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.4.463     Document Type: Review

References (130)

1. Hunter AM, Lacasse EC, Korneluk RG. The inhibitor of apoptosis (IAPs) as cancer targets. Apoptosis 2007;12:1543-68
2. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins; why XIAP is the black sheep of the family. EMBO Rep 2006;7:988-94
3. Vaux DL, Silke J. IAPs-the ubiquitin connection. Cell Death Differ 2005;12:1205-7
4. Marusawa H, Matsuzawa S, Welsh K, et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 2003;22:2729-40
5. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21
6. Muchmore SW, Chen J, Jakob C, et al. Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin. Mol Cell 2000;6:173-82
7. Li F, Ling X. Survivin study: an update of "what is the next wave?" J Cell Physiol 2006;208:476-86
8. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 2006;18:1-7
9. Lens SM, Vader G, Medema RH. The case for Survivin as mitotic regulator. Curr Opin Cell Biol 2006;18:616-22
10. Vagnarelli P, Earnshaw WC. Chromosomal passengers: the four-dimensional regulation of mitotic events. Chromosoma 2004;113:211-22
11. Honda R, Korner R, Nigg EA. Exploring the functional interactions between aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 2004;14:3325-41
12. Wheatley SP, Carvalho A, Vagnarelli P, Earnshaw WC. INCENP is required for proper targeting of survivin to the centromeres and the anaphase spindle during mitosis. Curr Biol 2001;11:886-90
13. Gassmann R, Carvalho A, Henzing AJ, et al. Borealin: a novel chromosomal passenger requied for stability of the bipolar mitotic spindle. J Cell Biol 2004;166:179-91
14. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-4
15. cdc2 phosphorylation of surviving. Proc Natl Acad Sci USA 2000;97:13103-7
16. Wheatley SP, Henzing AJ, Dodson H, et al. Aurora-B phosphorylation in vitro identifies a residue of survivin that is essential for its localization and binding to inner centromere protein (INCENP) in vivo. J Biol Chem 2004;279:5655-60
17. Vong QP, Cao K, Li HY, et al. Chromosome alignment and segregation regulated by ubiquitination of survivin. Science 2005;310:1499-504
18. Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of surviving. Proc Natl Acad Sci USA 2004;101:15100-5
19. Kim PJ, Plescia J, Clevers H, et al. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003;362:205-9
20. Gritsko T, Williams A, Turkson J, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006;12:11-9
21. Song J, So T, Cheng M, et al. Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 2005;22:621-31
22. Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1 /Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002;21:5673-83
23. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99
24. Xia F, Altieri DC. Mitosis-independent survivin gene expression in vivo and regulation by p53. Cancer Res 2006;66:3392-5
25. Dohi T, Okada K, Xia F, et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004;279:34087-90
26. Dohi T, Beltrami E, Wall NR, et al. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004;114:1117-27
27. Dohi T, Xia F, Altieri DC. Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell 2007;27:17-28
28. Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001;40:1117-23
29. Banks DP, Plescia J, Altieri DC, et al. Survivin does not inhibit caspase-3 activity. Blood 2000;96:4002-3
30. Knauer SK, Bier C, Habtemichael N, Stauber RH. The Survivin-Crm1 interaction is essential for chromosomal passenger complex localization and function. EMBO Rep 2006;7:1259-65
31. Colnaghi R, Connell CM, Barrett RMA, Wheatley SP. Separating the anti-apoptotic and mitotic roles of survivin. J Biol Chem 2006;281:33450-6
32. Stauber RH, Mann W, Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanisms, prognostic, and theraputic potential. Cancer Res 2007;67:5999-6002
33. Fortugno P, Beltrami E, Plescia J, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 2003;100:13791-6
34. Endoh T, Tsuji N, Asanuma K, et al. Survivin enhances telomerase activity via up-regulation of specificity protein 1-and c-Myc-mediated human telomerase reverse transcriptase gene transcription. Exp Cell Res 2005;305:300-11
35. Caldas H, Jiang Y, Holloway MP, et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005;24:1994-2007
36. Knauer SK, Bier C, Schlag P, et al. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 2007;6:1502-9
37. Caldas H, Honsey LE, Altura RA. Survivin 2α: a novel survivin splice variant expressed in human malignancies. Mol Cancer 2005;4:11. Published online 2 March 2005, doi:10.1186/1476-4598-4-11
38. Ling X, Cheng Q, Black JD, LiF. Forced expression of survivin-2b abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of bcl-2, bax, and survivin. J Biol Chem 2007;282:27204-14
39. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005;92:212-6
40. Islam A, Kageyama H, Takada N, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000;19:617-23
41. Taubert H, Kappler M, Bache M, et al. Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. Oncogene 2005;24:5258-61
42. Wagner M, Schmelz K, Wuchter C, et al. In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia. Int J Cancer 2006;119:1291-7
43. Krieg A, Mahotka C, Krieg T, et al. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 2002;86:737-43
44. Mahotka C, Krieg T, Krieg A, et al. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 2002;100:30-6
45. Fangusaro JR, Jiang Y, Holloway MP, et al. Survivin, survivin-2B, and survivin-deltaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 2005;92:359-65
46. Ryan B, O'Donovan N, Browne B, et al. Expression of survivin and its splice variants survivin-2B and survivin-ΔEx3 in breast cancer. Br J Cancer 2005;92:120-4
47. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006;5:1087-98
48. Li F, Brattain MG. Role of the survivin gene in pathophysiology. Am J Pathol 2006;169:1-11
49. Deguchi M, Shiraki K, Inoue H. Expression of survivin during liver regeneration. Biochem Biophys Res Commun 2002;297:59-64
50. Chiou SK, Moon WS, Jones MK, Tarnawski AS. Survivin expression in the stomach: implications for mucosal integrity and protection. Biochem Biophys Res Commun 2003;305:374-9
51. Johnson EA, Svetlov SI, Wang KK, et al. Cell-specific DNA fragmentation may be attenuated by a survivin-dependent mechanism after traumatic brain injury in rats. Exp Brain Res 2005;167:17-26
52. Conway EM, Zwerts F, Van Eygen V, et al. Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation. Am J Pathol 2003;163:935-46
53. Kindt N, Menzebach A, Van de Wouwer M, et al. Protective role of the inhibitor of apoptosis protein, survivin, in toxin-induced acute renal failure. FASEB J 2007;22(2):510-21
54. Lechler P, Wu X, Bernhardt W, et al. The tumor gene survivin is highly expressed in adult renal tubular cells: implications for a pathophysiological role in the kidney. Am J Pathol 2007;171:1483-98
55. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581-9
56. Florell SR, Bowen AR, Hanks AN, et al. Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi. J Cutan Pathol 2005;32:45-9
57. Vetter CS, Muller-Blech K, Schrama D, et al. Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions. Arch Dermatol Res 2005;297:26-30
58. Duffy MJ, O'Donovan N, Brennan DJ, et al. Survivin: a promising tumor biomarker. Cancer Lett 2007;249:49-60
59. Li F, Yang J, Ramnath N, et al. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 2005;114:509-12
60. Giodini A, Kallio MJ, Wall NR, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 2002;62:2462-7
61. Zaffaroni N, Pennati M, Colella G, et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002;59:1406-12
62. Zhang M, Mukherjee N, Bermudez RS, et al. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate 2005;64:293-302
63. O'Connor DS, Wall NR, Porter AC, Altieri DC. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2002;2:43-54
64. Zhou J, O'Brate A, Zelnak A, Giannakakou P. Survivin deregulation in β-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol. Cancer Res 2004;64:8708-14
65. Ling X, Bernacki RJ, Brattain MG, Li F. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem 2004;279:15196-203
66. Vaira V, Lee CW, Goel HL, et al. Regulation of survivin expression by IGF-1/mTOR signalling. Oncogene 2006;26:1-7
67. Nomura T, Yamasaki M, Nomura Y, Mimata H. Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol Rep 2005;14:993-7
68. Tirro E, Consoli ML, Massimino M, et al. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res 2006;66:4263-72
69. Van Geelen CM, De Vries EG, De Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat 2004;7:345-58
70. Zhang M, Latham DE, Delaney MA, Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005;24:2474-82
71. Span PN, Tjan-Heijnen VC, Manders P, et al. High survivin predicts a pooor response to endocrine therapy but a good response to chemotherapy in advanced breast cancer. Brest Cancer Res Treat 2006;98:223-30
72. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26
73. Asanuma K, Moriai R, Yajima T. Survivin as a radio-resistance factor in pancreatic cancer. Jpn J Cancer Res 2000;91:1204-9
74. Pennati M, Binda M, Colella G, et al. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol 2003;120:648-54
75. Rodel C, Haas J, Groth A, et al. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 2003;55:1341-7
76. Rodel F, Hoffmann J, Distet L, et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005;65:4881-7
77. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003;300:1155-9
78. Tran J, Master Z, Yu JL, et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002;99:4349-54
79. Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med 2005;9:360-72
80. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy; fulfilled promises and open questions. Carcinogenesis 2007;28:1133-9
81. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999;113:1076-81
82. Cao C, Mu Y, Hallahan DE, Lu B. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 2004;23:7047-52
83. Sharma H, Sen S, Lo Muzio L, et al. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol Ther 2005;4:720-7
84. Du ZX, Zhang HY, Gao Da X, et al. Antisurvivin oligonucleotides inhibit growth and induce apoptosis in human medullary thyroid carcinoma cells. Exp Mol Med 2006;38:230-40
85. Fuessel S, Kueppers B, Ning S, et al. Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells. J Urol 2004;171:2471-6
86. Ansell SM, Arendt BK, Grote DM, et al. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 2004;18:616-23
87. Sah NK, Munshi A, Hobbs M, et al. Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. Int J Radiat Oncot Biol Phys 2006;66:852-9
88. Kanwar JR, Shen W-P, Kanwar RK, et al. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Nat Cancer Inst 2001;93:1541-52
89. Pennati M, Colella G, Folini M, et al. Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest 2002;109:285-6
90. Pennati M, Binda M, De Cesare M, et al. Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis 2004;25:1129-36
91. Pennati M, Binda M, Colella G, et al. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 2004;23:386-94
92. Choi KS, Lee TH, Jung MH. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotica function of survivin in MCF-7 cells. Cancer Gene Ther 2003;10:87-95
93. Carvalho A, Carmena M, Sambade C, et al. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 2003;116:2987-98
94. Ai Z, Yin L, Zhou X, et al. Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer 2006;107:746-56
95. Paduano F, Villa R, Pennati M, et al. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther 2006;5:179-86
96. Nakao K, Hamasaki K, Ichikawa T, et al. Survivin downregulation by siRNA sensitizes human hepatoma cells to TRAIL-induced apoptosis. Oncol Rep 2006;16:389-92
97. Lens SM, Wolthuis RM, Klompmaker R, et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 2003;22:2934-47
98. Beltrami E, Plescia J, Wilkinson JC, et al. Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J Biol Chem 2004;279:2077-84
99. Jiang G, Li J, Zeng Z, Xian L. Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. Cancer Biol Ther 2006;5:435-40
100. Li QX, Zhao J, Liu JY, et al. Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther 2006;5:860-6
101. Yonesaka K, Tamura K, Kurata T, et al. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer 2006;118:812-20
102. Kappler M, Taubert H, Bartel F, et al. Radiosensitization after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncol Rep 2005;13:167-72
103. Coma S, Noe V, Lavarino C, et al. Use of siRNAs and antisense oligonucleotides against survivin RNA to inhibit steps leading to tumor angiogenesis. Oligonucleotides 2004;14:100-3
104. Wuttig D, Kunze D, Fuessel S, et al. Are overexpressed alternative survivin transcripts in human bladder cancer suitable targets for siRNA-mediated in vitro inhibition? Int J Oncol 2007;30:1317-24
105. Kappler M, Rot S, Taubert H, et al. The effects of knockdown of wild-type survivin, survivin-2B or survivin-Δ3 on the radiosensitization in a soft tissue sarcoma cells in vitro under different oxygen conditions. Cancer Gene Ther 2007;14:994-1001
106. Pennati M, Campbell AJ, Curto M, et al. Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol CancerTher 2005;4:1328-37
107. Plescia J, Salz W, Xia F, et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005;7:457-68
108. Gyurkocza B, Plescia J, Raskett CM, et al. Antileukemic activity of shepherdin and molecular diversity of Hsp90 inhibitors. J Natl Cancer Inst 2006;98:1068-77
109. Meli M, Pennati M, Curto M, et al. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead. J Med Chem 2006;49:7721-30
110. Chang CC, Heller JD, Kuo J, Huang RC. Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci USA 2004;101:13239-44
111. Park R, Chang CC, Liang YC, et al. Systemic treatment with tetra-O-methyl nordihydroguaiaretic acid suppresses the growth of human xenograft tumors. Clin Cancer Res 2005;1112:4601-9
112. Huang RC, Chang CC, Mold D. Survivin-dependent and -independent pathways and the induction of cancer cell death by tetra-O-methyl nordihydroguaiaretic acid. Semin Oncol 2006;33:479-85
113. Nakahara T, Takeuchi M, Kinoyama I, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007;67:8014-21
114. Mita MM, Mita AC, Tolcher AW. Apoptosis: mechanism and implications for cancer therapeutics. Targ Oncol 2006;1:197-214
115. Tu SP, Cui JT, Liston P, et al. Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology 2005;128:361-75
116. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 2001;98:635-40
117. Mesri M, Wall NR, Li J, et al. Cancer gene therapy using a survivin mutant adneovirus. J Clin Invest 2001;108:981-90
118. Yan H, Thomas J, Liu T, et al. Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist. Oncogene 2006;25:6968-74
119. Lo HW, Day CP, Hung MC. Cancer-specific gene therapy. Adv Genet 2005;54:235-55
120. Chen JS, Liu JC, Shen L, et al. Cancer-specific acrivation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther 2004;11:740-7
121. Van Houdt WJ, Haviv YS, Lu B, et al. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg 2006;104:583-92
122. Andersen MH, Thor SP. Survivin-a universal tumor antigen. Histol Histopathol 2002;17:669-75
123. Rohayem J, Diestelkoetter P, Weigle B, et al. Antibody response to the tumor-associated inhibitor of apoptosis protein in cancer patients. Cancer Res 2000;60:1815-7
124. Schmidt SM, Schag K, Muller MR, et al. Survivin is a shered tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003;102:571-6
125. Schmitz M, Diestelkoetter P, Weigle B, et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000;60:4845-9
126. Reker S, Meier A, Holten-Andersen L, et al. Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther 2004;3:173-9
127. Otto K, Andersen MH, Eggert A, et al. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 2005;23:884-9
128. Tsuruma T, Hata F, Torigoe T, et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004;2:19. Published online 13 June 2004, doi:10.1186/1479-5876-2-19
129. Wobser M, Keikavoussi P, Kunzmann V, et al. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006;55:1294-8
130. Fuessel S, Meye A, Schmitz M, et al. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate 2006;66:811-21